Clinical trials: Rilpivirine

HIV-1 Infection

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

• Completed
• Age: 18 years and older
• Phase 3
• Results posted

The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir…

Trial name

NCT02345252

Testing

FTC/RPV/TAF, FTC/RPV/TDF

Where

117 sites in United States, Belgium and 10 more

Volunteers

632 people

Sponsor

Gilead Sciences